American Journal of Cardiology
Volume 101, Issue 8, Supplement , Pages S27-S35 , 17 April 2008

Reducing the Residual Risk of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy With Combination Therapy

  • Tamar S. Polonsky, MD
    • ,
  • Michael H. Davidson, MD

      Affiliations

    • Corresponding Author InformationAddress for reprints: Michael H. Davidson, MD, University of Chicago, Pritzker School of Medicine, 5758 South Maryland Avenue, MC 9024, Chicago, Illinois 60637-1470.

References 

  1. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdfAccessed December 28, 2007
  2. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239
  3. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–1310
  4. Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006;368:919–928
  5. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Eng J Med. 2005;352:1425–1435
  6. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504
  7. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 participants with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  8. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7–22
  9. De Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KAA, White HD, et al Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes. JAMA. 2004;292:1307–1316
  10. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278
  11. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438–445
  12. Pederson TR, Faergeman O, Kastelein JJP, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437–2445
  13. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels (The Framingham Study). JAMA. 1986;256:2835–2838
  14. Assmann G, Gotto AM. HDL cholesterol and protective factors in atherosclerosis. Circulation. 2004;109(suppl):iii8–iii14
  15. Gordon DJ, Rifkind BM. High-density lipoprotein: the clinical implication of recent studies. N Engl J Med. 1989;321:1311–1316
  16. Chapmann MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C. Raising high-density cholesterol with reduction of cardiovascular risk: the role of nicotinic acid—a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin. 2004;20:1253–1268
  17. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA. 2007;298:786–798
  18. Spieker LE, Sudano I, Hurlimann D, Lerch PG, Lang MG, Binggeli C, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002;105:1399–1402
  19. Cockerill GW, Huehns TY, Weerasinghe A, Stocker C, Lerch PG, Miller NE, et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation. 2001;103:108–112
  20. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR trial). Am J Cardiol. 2003;92:152–160
  21. Gotto AM, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, et al Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101:477–484
  22. The Long-Term Intervention With Pravastatin in Ischaemic Disease Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357
  23. Blankenhorn DH, Johnson RL, Nessim SA, Azen SP, Sanmarco ME, Selzer RH. The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results. Control Clin Trials. 1987;8:356–387
  24. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, et al Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297:499–508
  25. Sacks FM, Rouleau J-L, Moye LA, Pfeffer MA, Warnica JW, Arnold JMO, et al Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels. Am J Cardiol. 1995;75:621–623
  26. LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H Treating to New Targets (TNT) Steering Committee and Investigators. Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the Treating to New Targets [TNT] study). Am J Cardiol. 2007;100:747–752
  27. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81(suppl):7B–12B
  28. Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J. 1998;19(suppl):M8–M14
  29. Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, et al. Results of the National Cholesterol Education Program (NCEP) Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey: implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005;96:556–563
  30. Jacobson TA, Miller M, Schaefer EJ. Hypertriglyceridemia and cardiovascular risk reduction. Clin Ther. 2007;29:763–777
  31. McKenney JM, Sica D. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. Pharmacotherapy. 2007;27:715–728
  32. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome and risk of incident cardiovascular events. Circulation. 2003;107:391–397
  33. Gardner CD, Fortmann SP, Krause R. Association of small LDL particles with incidence of coronary artery disease in men and women. JAMA. 1996;276:875–881
  34. Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation. 2004;109:1349–1353
  35. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–1565
  36. Kinlay S, Schwartz GG, Anders GO, Rifai N, Leslie SJ, Sasiela WJ, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108:1560–1566
  37. Chan AW, Bhatt DL, Chew DP, Reginelli J, Schneider JP, Topol EJ, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation. 2003;107:1750–1756
  38. Nissen SE, Tuzcu EM, Schoenhagen P. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29–38
  39. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–28
  40. Shepherd J, Blauw GJ, Murphy MB, Bollen El, Buckley MG, Cobbe SM, et al Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002;360:1623–1630
  41. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet. 2003;361:1149–1158
  42. Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, et al Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation. 2005;112:171–178
  43. Nissen SE. Halting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis With Aggressive Lipid Lowering (REVERSAL) trial. Am J Med. 2005;118(suppl):22–27
  44. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double blind placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512–3517
  45. Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E PROVE IT–TIMI 22 [Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22] Investigators. Impact of triglyceride levels beyond low-density lipoprotein after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51:724–730

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9149(08)00367-6

doi: 10.1016/j.amjcard.2008.02.051

American Journal of Cardiology
Volume 101, Issue 8, Supplement , Pages S27-S35 , 17 April 2008

Article Tools

* Image Usage & Resolution